Therefore, BCMA-targeting treatments might be a more advanced target in breast cancer, especially as BCMA seems to correlate with an established checkpoint molecule, PDL-1 (see the previous paragraph and Figure 5E). Here, TNFRSF17 is linked to breast carcinoma.